nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—RYR2—prostate gland—urinary bladder cancer	0.0419	0.0954	CbGeAlD
Hydralazine—RYR2—seminal vesicle—urinary bladder cancer	0.0355	0.0807	CbGeAlD
Hydralazine—RYR2—smooth muscle tissue—urinary bladder cancer	0.0297	0.0676	CbGeAlD
Hydralazine—RYR2—urethra—urinary bladder cancer	0.0281	0.0639	CbGeAlD
Hydralazine—AOC3—prostate gland—urinary bladder cancer	0.0252	0.0575	CbGeAlD
Hydralazine—RYR2—female reproductive system—urinary bladder cancer	0.0229	0.0521	CbGeAlD
Hydralazine—AOC3—seminal vesicle—urinary bladder cancer	0.0214	0.0486	CbGeAlD
Hydralazine—RYR2—vagina—urinary bladder cancer	0.0207	0.0471	CbGeAlD
Hydralazine—P4HA1—prostate gland—urinary bladder cancer	0.0202	0.0459	CbGeAlD
Hydralazine—AOC3—smooth muscle tissue—urinary bladder cancer	0.0179	0.0407	CbGeAlD
Hydralazine—AOC3—renal system—urinary bladder cancer	0.0172	0.0392	CbGeAlD
Hydralazine—P4HA1—seminal vesicle—urinary bladder cancer	0.0171	0.0389	CbGeAlD
Hydralazine—AOC3—urethra—urinary bladder cancer	0.0169	0.0385	CbGeAlD
Hydralazine—CYP3A4—urine—urinary bladder cancer	0.0149	0.0339	CbGeAlD
Hydralazine—P4HA1—smooth muscle tissue—urinary bladder cancer	0.0143	0.0325	CbGeAlD
Hydralazine—AOC3—female reproductive system—urinary bladder cancer	0.0138	0.0314	CbGeAlD
Hydralazine—P4HA1—renal system—urinary bladder cancer	0.0138	0.0313	CbGeAlD
Hydralazine—P4HA1—urethra—urinary bladder cancer	0.0135	0.0308	CbGeAlD
Hydralazine—AOC3—vagina—urinary bladder cancer	0.0125	0.0284	CbGeAlD
Hydralazine—P4HA1—female reproductive system—urinary bladder cancer	0.011	0.0251	CbGeAlD
Hydralazine—P4HA1—vagina—urinary bladder cancer	0.00996	0.0227	CbGeAlD
Hydralazine—AOC3—lymph node—urinary bladder cancer	0.00806	0.0183	CbGeAlD
Hydralazine—P4HA1—lymph node—urinary bladder cancer	0.00645	0.0147	CbGeAlD
Hydralazine—CYP3A4—renal system—urinary bladder cancer	0.00365	0.0083	CbGeAlD
Hydralazine—CYP3A4—female reproductive system—urinary bladder cancer	0.00292	0.00665	CbGeAlD
Hydralazine—Leukopenia—Cisplatin—urinary bladder cancer	0.00121	0.00216	CcSEcCtD
Hydralazine—Constipation—Thiotepa—urinary bladder cancer	0.0012	0.00215	CcSEcCtD
Hydralazine—Discomfort—Fluorouracil—urinary bladder cancer	0.0012	0.00214	CcSEcCtD
Hydralazine—Purpura—Epirubicin—urinary bladder cancer	0.0012	0.00214	CcSEcCtD
Hydralazine—Vascular purpura—Doxorubicin—urinary bladder cancer	0.00119	0.00213	CcSEcCtD
Hydralazine—Muscle spasms—Etoposide—urinary bladder cancer	0.00119	0.00213	CcSEcCtD
Hydralazine—Oedema—Gemcitabine—urinary bladder cancer	0.00119	0.00211	CcSEcCtD
Hydralazine—Cardiac failure—Epirubicin—urinary bladder cancer	0.00118	0.00211	CcSEcCtD
Hydralazine—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.00118	0.0021	CcSEcCtD
Hydralazine—Oedema—Fluorouracil—urinary bladder cancer	0.00117	0.00208	CcSEcCtD
Hydralazine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00116	0.00207	CcSEcCtD
Hydralazine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00116	0.00207	CcSEcCtD
Hydralazine—Renal failure acute—Doxorubicin—urinary bladder cancer	0.00116	0.00206	CcSEcCtD
Hydralazine—Myalgia—Cisplatin—urinary bladder cancer	0.00115	0.00206	CcSEcCtD
Hydralazine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00115	0.00205	CcSEcCtD
Hydralazine—Anxiety—Cisplatin—urinary bladder cancer	0.00115	0.00205	CcSEcCtD
Hydralazine—Anaemia—Etoposide—urinary bladder cancer	0.00115	0.00204	CcSEcCtD
Hydralazine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00114	0.00203	CcSEcCtD
Hydralazine—Discomfort—Cisplatin—urinary bladder cancer	0.00114	0.00203	CcSEcCtD
Hydralazine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00114	0.00203	CcSEcCtD
Hydralazine—Anorexia—Gemcitabine—urinary bladder cancer	0.00113	0.00201	CcSEcCtD
Hydralazine—Urticaria—Thiotepa—urinary bladder cancer	0.00112	0.002	CcSEcCtD
Hydralazine—Malaise—Etoposide—urinary bladder cancer	0.00112	0.00199	CcSEcCtD
Hydralazine—Body temperature increased—Thiotepa—urinary bladder cancer	0.00111	0.00199	CcSEcCtD
Hydralazine—Anorexia—Fluorouracil—urinary bladder cancer	0.00111	0.00198	CcSEcCtD
Hydralazine—Leukopenia—Etoposide—urinary bladder cancer	0.00111	0.00198	CcSEcCtD
Hydralazine—Purpura—Doxorubicin—urinary bladder cancer	0.00111	0.00198	CcSEcCtD
Hydralazine—Hypotension—Gemcitabine—urinary bladder cancer	0.00111	0.00198	CcSEcCtD
Hydralazine—Oedema—Cisplatin—urinary bladder cancer	0.0011	0.00197	CcSEcCtD
Hydralazine—Cardiac failure—Doxorubicin—urinary bladder cancer	0.00109	0.00195	CcSEcCtD
Hydralazine—Hypotension—Fluorouracil—urinary bladder cancer	0.00109	0.00194	CcSEcCtD
Hydralazine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00108	0.00193	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00108	0.00193	CcSEcCtD
Hydralazine—Tachycardia—Cisplatin—urinary bladder cancer	0.00108	0.00192	CcSEcCtD
Hydralazine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00106	0.0019	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00106	0.00189	CcSEcCtD
Hydralazine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00106	0.00188	CcSEcCtD
Hydralazine—Eosinophilia—Methotrexate—urinary bladder cancer	0.00106	0.00188	CcSEcCtD
Hydralazine—Anorexia—Cisplatin—urinary bladder cancer	0.00105	0.00188	CcSEcCtD
Hydralazine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00105	0.00187	CcSEcCtD
Hydralazine—Discomfort—Etoposide—urinary bladder cancer	0.00104	0.00186	CcSEcCtD
Hydralazine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00104	0.00185	CcSEcCtD
Hydralazine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00104	0.00185	CcSEcCtD
Hydralazine—Hypotension—Cisplatin—urinary bladder cancer	0.00103	0.00184	CcSEcCtD
Hydralazine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00103	0.00184	CcSEcCtD
Hydralazine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00103	0.00183	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00102	0.00182	CcSEcCtD
Hydralazine—Constipation—Gemcitabine—urinary bladder cancer	0.00101	0.00181	CcSEcCtD
Hydralazine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00101	0.00181	CcSEcCtD
Hydralazine—Pancytopenia—Methotrexate—urinary bladder cancer	0.00101	0.00181	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00101	0.0018	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00101	0.00179	CcSEcCtD
Hydralazine—Neutropenia—Methotrexate—urinary bladder cancer	0.000997	0.00178	CcSEcCtD
Hydralazine—Dysuria—Methotrexate—urinary bladder cancer	0.000997	0.00178	CcSEcCtD
Hydralazine—Pruritus—Thiotepa—urinary bladder cancer	0.000997	0.00178	CcSEcCtD
Hydralazine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000992	0.00177	CcSEcCtD
Hydralazine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000991	0.00177	CcSEcCtD
Hydralazine—Tachycardia—Etoposide—urinary bladder cancer	0.000988	0.00176	CcSEcCtD
Hydralazine—Eosinophilia—Epirubicin—urinary bladder cancer	0.000988	0.00176	CcSEcCtD
Hydralazine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000985	0.00176	CcSEcCtD
Hydralazine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000977	0.00174	CcSEcCtD
Hydralazine—Angina pectoris—Epirubicin—urinary bladder cancer	0.000972	0.00173	CcSEcCtD
Hydralazine—Anorexia—Etoposide—urinary bladder cancer	0.000965	0.00172	CcSEcCtD
Hydralazine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000964	0.00172	CcSEcCtD
Hydralazine—Decreased appetite—Cisplatin—urinary bladder cancer	0.00096	0.00171	CcSEcCtD
Hydralazine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00096	0.00171	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000954	0.0017	CcSEcCtD
Hydralazine—Depression—Methotrexate—urinary bladder cancer	0.000948	0.00169	CcSEcCtD
Hydralazine—Pancytopenia—Epirubicin—urinary bladder cancer	0.000947	0.00169	CcSEcCtD
Hydralazine—Hypotension—Etoposide—urinary bladder cancer	0.000946	0.00169	CcSEcCtD
Hydralazine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000937	0.00167	CcSEcCtD
Hydralazine—Dysuria—Epirubicin—urinary bladder cancer	0.000933	0.00166	CcSEcCtD
Hydralazine—Neutropenia—Epirubicin—urinary bladder cancer	0.000933	0.00166	CcSEcCtD
Hydralazine—Dizziness—Thiotepa—urinary bladder cancer	0.000932	0.00166	CcSEcCtD
Hydralazine—Urticaria—Fluorouracil—urinary bladder cancer	0.000926	0.00165	CcSEcCtD
Hydralazine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000924	0.00165	CcSEcCtD
Hydralazine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000921	0.00164	CcSEcCtD
Hydralazine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000914	0.00163	CcSEcCtD
Hydralazine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00091	0.00162	CcSEcCtD
Hydralazine—Paraesthesia—Etoposide—urinary bladder cancer	0.000909	0.00162	CcSEcCtD
Hydralazine—Haematuria—Methotrexate—urinary bladder cancer	0.000906	0.00162	CcSEcCtD
Hydralazine—Weight decreased—Epirubicin—urinary bladder cancer	0.000902	0.00161	CcSEcCtD
Hydralazine—Dyspnoea—Etoposide—urinary bladder cancer	0.000902	0.00161	CcSEcCtD
Hydralazine—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000899	0.0016	CcSEcCtD
Hydralazine—Vomiting—Thiotepa—urinary bladder cancer	0.000896	0.0016	CcSEcCtD
Hydralazine—Rash—Thiotepa—urinary bladder cancer	0.000888	0.00158	CcSEcCtD
Hydralazine—Dermatitis—Thiotepa—urinary bladder cancer	0.000887	0.00158	CcSEcCtD
Hydralazine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000887	0.00158	CcSEcCtD
Hydralazine—Headache—Thiotepa—urinary bladder cancer	0.000883	0.00157	CcSEcCtD
Hydralazine—Decreased appetite—Etoposide—urinary bladder cancer	0.00088	0.00157	CcSEcCtD
Hydralazine—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000876	0.00156	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000874	0.00156	CcSEcCtD
Hydralazine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000873	0.00156	CcSEcCtD
Hydralazine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000872	0.00156	CcSEcCtD
Hydralazine—Jaundice—Epirubicin—urinary bladder cancer	0.000867	0.00155	CcSEcCtD
Hydralazine—Constipation—Etoposide—urinary bladder cancer	0.000865	0.00154	CcSEcCtD
Hydralazine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000864	0.00154	CcSEcCtD
Hydralazine—Neutropenia—Doxorubicin—urinary bladder cancer	0.000863	0.00154	CcSEcCtD
Hydralazine—Dysuria—Doxorubicin—urinary bladder cancer	0.000863	0.00154	CcSEcCtD
Hydralazine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000858	0.00153	CcSEcCtD
Hydralazine—Hepatitis—Methotrexate—urinary bladder cancer	0.000853	0.00152	CcSEcCtD
Hydralazine—Haematuria—Epirubicin—urinary bladder cancer	0.000848	0.00151	CcSEcCtD
Hydralazine—Pruritus—Gemcitabine—urinary bladder cancer	0.000838	0.0015	CcSEcCtD
Hydralazine—Nausea—Thiotepa—urinary bladder cancer	0.000837	0.00149	CcSEcCtD
Hydralazine—Weight decreased—Doxorubicin—urinary bladder cancer	0.000835	0.00149	CcSEcCtD
Hydralazine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000834	0.00149	CcSEcCtD
Hydralazine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00083	0.00148	CcSEcCtD
Hydralazine—Pruritus—Fluorouracil—urinary bladder cancer	0.000824	0.00147	CcSEcCtD
Hydralazine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000814	0.00145	CcSEcCtD
Hydralazine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000811	0.00145	CcSEcCtD
Hydralazine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000807	0.00144	CcSEcCtD
Hydralazine—Urticaria—Etoposide—urinary bladder cancer	0.000804	0.00143	CcSEcCtD
Hydralazine—Jaundice—Doxorubicin—urinary bladder cancer	0.000802	0.00143	CcSEcCtD
Hydralazine—Body temperature increased—Etoposide—urinary bladder cancer	0.0008	0.00143	CcSEcCtD
Hydralazine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.0008	0.00143	CcSEcCtD
Hydralazine—Hepatitis—Epirubicin—urinary bladder cancer	0.000798	0.00142	CcSEcCtD
Hydralazine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000797	0.00142	CcSEcCtD
Hydralazine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000794	0.00142	CcSEcCtD
Hydralazine—Haematuria—Doxorubicin—urinary bladder cancer	0.000785	0.0014	CcSEcCtD
Hydralazine—Dizziness—Fluorouracil—urinary bladder cancer	0.00077	0.00137	CcSEcCtD
Hydralazine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000768	0.00137	CcSEcCtD
Hydralazine—Chills—Methotrexate—urinary bladder cancer	0.000765	0.00137	CcSEcCtD
Hydralazine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000756	0.00135	CcSEcCtD
Hydralazine—Vomiting—Gemcitabine—urinary bladder cancer	0.000753	0.00134	CcSEcCtD
Hydralazine—Rash—Gemcitabine—urinary bladder cancer	0.000747	0.00133	CcSEcCtD
Hydralazine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000746	0.00133	CcSEcCtD
Hydralazine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000746	0.00133	CcSEcCtD
Hydralazine—Headache—Gemcitabine—urinary bladder cancer	0.000742	0.00132	CcSEcCtD
Hydralazine—Flushing—Epirubicin—urinary bladder cancer	0.000741	0.00132	CcSEcCtD
Hydralazine—Vomiting—Fluorouracil—urinary bladder cancer	0.000741	0.00132	CcSEcCtD
Hydralazine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000739	0.00132	CcSEcCtD
Hydralazine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000735	0.00131	CcSEcCtD
Hydralazine—Rash—Fluorouracil—urinary bladder cancer	0.000735	0.00131	CcSEcCtD
Hydralazine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000734	0.00131	CcSEcCtD
Hydralazine—Headache—Fluorouracil—urinary bladder cancer	0.00073	0.0013	CcSEcCtD
Hydralazine—Chills—Epirubicin—urinary bladder cancer	0.000716	0.00128	CcSEcCtD
Hydralazine—Pruritus—Etoposide—urinary bladder cancer	0.000716	0.00128	CcSEcCtD
Hydralazine—Nausea—Gemcitabine—urinary bladder cancer	0.000704	0.00126	CcSEcCtD
Hydralazine—Vomiting—Cisplatin—urinary bladder cancer	0.000702	0.00125	CcSEcCtD
Hydralazine—Rash—Cisplatin—urinary bladder cancer	0.000696	0.00124	CcSEcCtD
Hydralazine—Dermatitis—Cisplatin—urinary bladder cancer	0.000696	0.00124	CcSEcCtD
Hydralazine—Diarrhoea—Etoposide—urinary bladder cancer	0.000692	0.00124	CcSEcCtD
Hydralazine—Nausea—Fluorouracil—urinary bladder cancer	0.000692	0.00123	CcSEcCtD
Hydralazine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000689	0.00123	CcSEcCtD
Hydralazine—Anaemia—Methotrexate—urinary bladder cancer	0.000686	0.00122	CcSEcCtD
Hydralazine—Flushing—Doxorubicin—urinary bladder cancer	0.000686	0.00122	CcSEcCtD
Hydralazine—Malaise—Methotrexate—urinary bladder cancer	0.00067	0.00119	CcSEcCtD
Hydralazine—Dizziness—Etoposide—urinary bladder cancer	0.000669	0.00119	CcSEcCtD
Hydralazine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000668	0.00119	CcSEcCtD
Hydralazine—Leukopenia—Methotrexate—urinary bladder cancer	0.000665	0.00119	CcSEcCtD
Hydralazine—Chills—Doxorubicin—urinary bladder cancer	0.000663	0.00118	CcSEcCtD
Hydralazine—Nausea—Cisplatin—urinary bladder cancer	0.000656	0.00117	CcSEcCtD
Hydralazine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000645	0.00115	CcSEcCtD
Hydralazine—Vomiting—Etoposide—urinary bladder cancer	0.000643	0.00115	CcSEcCtD
Hydralazine—Anaemia—Epirubicin—urinary bladder cancer	0.000642	0.00115	CcSEcCtD
Hydralazine—Agitation—Epirubicin—urinary bladder cancer	0.000639	0.00114	CcSEcCtD
Hydralazine—Rash—Etoposide—urinary bladder cancer	0.000638	0.00114	CcSEcCtD
Hydralazine—Dermatitis—Etoposide—urinary bladder cancer	0.000637	0.00114	CcSEcCtD
Hydralazine—Headache—Etoposide—urinary bladder cancer	0.000634	0.00113	CcSEcCtD
Hydralazine—Arthralgia—Methotrexate—urinary bladder cancer	0.000632	0.00113	CcSEcCtD
Hydralazine—Myalgia—Methotrexate—urinary bladder cancer	0.000632	0.00113	CcSEcCtD
Hydralazine—Malaise—Epirubicin—urinary bladder cancer	0.000627	0.00112	CcSEcCtD
Hydralazine—Discomfort—Methotrexate—urinary bladder cancer	0.000625	0.00111	CcSEcCtD
Hydralazine—Leukopenia—Epirubicin—urinary bladder cancer	0.000622	0.00111	CcSEcCtD
Hydralazine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000618	0.0011	CcSEcCtD
Hydralazine—Palpitations—Epirubicin—urinary bladder cancer	0.000614	0.0011	CcSEcCtD
Hydralazine—Nausea—Etoposide—urinary bladder cancer	0.000601	0.00107	CcSEcCtD
Hydralazine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000597	0.00106	CcSEcCtD
Hydralazine—Anaemia—Doxorubicin—urinary bladder cancer	0.000594	0.00106	CcSEcCtD
Hydralazine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000593	0.00106	CcSEcCtD
Hydralazine—Myalgia—Epirubicin—urinary bladder cancer	0.000592	0.00106	CcSEcCtD
Hydralazine—Arthralgia—Epirubicin—urinary bladder cancer	0.000592	0.00106	CcSEcCtD
Hydralazine—Agitation—Doxorubicin—urinary bladder cancer	0.000591	0.00105	CcSEcCtD
Hydralazine—Anxiety—Epirubicin—urinary bladder cancer	0.00059	0.00105	CcSEcCtD
Hydralazine—Discomfort—Epirubicin—urinary bladder cancer	0.000585	0.00104	CcSEcCtD
Hydralazine—Malaise—Doxorubicin—urinary bladder cancer	0.00058	0.00103	CcSEcCtD
Hydralazine—Anorexia—Methotrexate—urinary bladder cancer	0.000578	0.00103	CcSEcCtD
Hydralazine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000576	0.00103	CcSEcCtD
Hydralazine—Palpitations—Doxorubicin—urinary bladder cancer	0.000568	0.00101	CcSEcCtD
Hydralazine—Oedema—Epirubicin—urinary bladder cancer	0.000567	0.00101	CcSEcCtD
Hydralazine—Hypotension—Methotrexate—urinary bladder cancer	0.000566	0.00101	CcSEcCtD
Hydralazine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000555	0.000991	CcSEcCtD
Hydralazine—Tachycardia—Epirubicin—urinary bladder cancer	0.000554	0.000988	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000552	0.000985	CcSEcCtD
Hydralazine—Myalgia—Doxorubicin—urinary bladder cancer	0.000547	0.000977	CcSEcCtD
Hydralazine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000547	0.000977	CcSEcCtD
Hydralazine—Anxiety—Doxorubicin—urinary bladder cancer	0.000546	0.000973	CcSEcCtD
Hydralazine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000544	0.000971	CcSEcCtD
Hydralazine—Discomfort—Doxorubicin—urinary bladder cancer	0.000541	0.000965	CcSEcCtD
Hydralazine—Anorexia—Epirubicin—urinary bladder cancer	0.000541	0.000964	CcSEcCtD
Hydralazine—Dyspnoea—Methotrexate—urinary bladder cancer	0.00054	0.000964	CcSEcCtD
Hydralazine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000534	0.000952	CcSEcCtD
Hydralazine—Hypotension—Epirubicin—urinary bladder cancer	0.00053	0.000945	CcSEcCtD
Hydralazine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000527	0.00094	CcSEcCtD
Hydralazine—Oedema—Doxorubicin—urinary bladder cancer	0.000525	0.000936	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000523	0.000933	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000517	0.000922	CcSEcCtD
Hydralazine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000514	0.000917	CcSEcCtD
Hydralazine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000512	0.000914	CcSEcCtD
Hydralazine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000509	0.000909	CcSEcCtD
Hydralazine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000506	0.000902	CcSEcCtD
Hydralazine—Anorexia—Doxorubicin—urinary bladder cancer	0.0005	0.000892	CcSEcCtD
Hydralazine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000499	0.000891	CcSEcCtD
Hydralazine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000499	0.000891	CcSEcCtD
Hydralazine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000493	0.00088	CcSEcCtD
Hydralazine—Hypotension—Doxorubicin—urinary bladder cancer	0.00049	0.000875	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00049	0.000874	CcSEcCtD
Hydralazine—Constipation—Epirubicin—urinary bladder cancer	0.000485	0.000865	CcSEcCtD
Hydralazine—Urticaria—Methotrexate—urinary bladder cancer	0.000482	0.000859	CcSEcCtD
Hydralazine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000479	0.000855	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000478	0.000853	CcSEcCtD
Hydralazine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000471	0.000841	CcSEcCtD
Hydralazine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000468	0.000835	CcSEcCtD
Hydralazine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000467	0.000834	CcSEcCtD
Hydralazine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000462	0.000824	CcSEcCtD
Hydralazine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000456	0.000814	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000453	0.000808	CcSEcCtD
Hydralazine—Urticaria—Epirubicin—urinary bladder cancer	0.000451	0.000804	CcSEcCtD
Hydralazine—Constipation—Doxorubicin—urinary bladder cancer	0.000449	0.000801	CcSEcCtD
Hydralazine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000448	0.0008	CcSEcCtD
Hydralazine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000447	0.000797	CcSEcCtD
Hydralazine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000432	0.000771	CcSEcCtD
Hydralazine—Pruritus—Methotrexate—urinary bladder cancer	0.000429	0.000765	CcSEcCtD
Hydralazine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000418	0.000745	CcSEcCtD
Hydralazine—Urticaria—Doxorubicin—urinary bladder cancer	0.000417	0.000744	CcSEcCtD
Hydralazine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000415	0.00074	CcSEcCtD
Hydralazine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000415	0.00074	CcSEcCtD
Hydralazine—Pruritus—Epirubicin—urinary bladder cancer	0.000401	0.000716	CcSEcCtD
Hydralazine—Dizziness—Methotrexate—urinary bladder cancer	0.000401	0.000715	CcSEcCtD
Hydralazine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000388	0.000692	CcSEcCtD
Hydralazine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000387	0.00069	CcSEcCtD
Hydralazine—Vomiting—Methotrexate—urinary bladder cancer	0.000385	0.000687	CcSEcCtD
Hydralazine—Rash—Methotrexate—urinary bladder cancer	0.000382	0.000682	CcSEcCtD
Hydralazine—Dermatitis—Methotrexate—urinary bladder cancer	0.000382	0.000681	CcSEcCtD
Hydralazine—Headache—Methotrexate—urinary bladder cancer	0.00038	0.000677	CcSEcCtD
Hydralazine—Dizziness—Epirubicin—urinary bladder cancer	0.000375	0.000669	CcSEcCtD
Hydralazine—Pruritus—Doxorubicin—urinary bladder cancer	0.000371	0.000662	CcSEcCtD
Hydralazine—Vomiting—Epirubicin—urinary bladder cancer	0.000361	0.000643	CcSEcCtD
Hydralazine—Nausea—Methotrexate—urinary bladder cancer	0.00036	0.000642	CcSEcCtD
Hydralazine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000359	0.000641	CcSEcCtD
Hydralazine—Rash—Epirubicin—urinary bladder cancer	0.000358	0.000638	CcSEcCtD
Hydralazine—Dermatitis—Epirubicin—urinary bladder cancer	0.000357	0.000637	CcSEcCtD
Hydralazine—Headache—Epirubicin—urinary bladder cancer	0.000355	0.000634	CcSEcCtD
Hydralazine—Dizziness—Doxorubicin—urinary bladder cancer	0.000347	0.000619	CcSEcCtD
Hydralazine—Nausea—Epirubicin—urinary bladder cancer	0.000337	0.000601	CcSEcCtD
Hydralazine—Vomiting—Doxorubicin—urinary bladder cancer	0.000334	0.000595	CcSEcCtD
Hydralazine—Rash—Doxorubicin—urinary bladder cancer	0.000331	0.00059	CcSEcCtD
Hydralazine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000331	0.00059	CcSEcCtD
Hydralazine—Headache—Doxorubicin—urinary bladder cancer	0.000329	0.000587	CcSEcCtD
Hydralazine—Nausea—Doxorubicin—urinary bladder cancer	0.000312	0.000556	CcSEcCtD
